Watch Jilin Province Huinan Changlong Bio-pharmacy Co Ltd for free: we tell you when fair value or trend changes.

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd stock HK$7.94, price HK$2.65, upside +199.6%, quality 79 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

26 models, one by oneBear HK$5.64 to bull HK$9.85 Growth analysisrevenue history, year by year Quality 79/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Home China · ISIN CNE100000130

Thin data Nov 8, 2026

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd

8049 · HK

Meets all rules

The stock costs 67% less than our calculation considers fair.

Fair value HK$7.94 · Strongly undervalued

Quality 79/100

Healthy Growth (revenue 5y +7.7 %/yr in CNY)

Highly profitable · 24.4% net margin (TTM)

Low debt

Generates free cash flow

Ranks above peers (13/14)

Even on cautious assumptions the value is 113% above the price (HK$5.64).

Wide moat 73/100 · thin data

Thin data

Watch Jilin Province Huinan Changlong Bio-pharmacy Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range HK$0.4500 – HK$2.73 · fair‑value band HK$5.64 – HK$9.85 · the HK$2.65 price screens below the HK$7.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Jilin Province Huinan Changlong Bio-pharmacy Co in your weekly email

Every Wednesday you see whether Jilin Province Huinan Changlong Bio-pharmacy Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jilin Province Huinan Changlong Bio-pharmacy Company Limited manufactures and distributes Chinese medicines and pharmaceutical products under the Changlong and Qing Tong brands in the People's Republic of China.

Show moreShow less

The company provides Edaravone injection, compound brain comfort capsules, haikun kidney capsules, cefpirome sulfate for injections, Cefpiramide for injections, anti-bone hyperplasia tablets, Lysine zinc gluconate tablets, and Qianlie Guihuang Tablets.

It also engages in the manufacture and distribution of beverages and prepackaged food, as well as health products. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited.

Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Kowloon, Hong Kong.

Stock analysis

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) currently trades at HK$2.65, while our model-based Fair Value estimate is HK$7.94, implying the stock looks roughly 67% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of HK$8.61 per share, and 25 of the 26 models we run sit above the HK$2.65 price.

Bear case: the Dividend Discount group reads lowest at HK$3.05, and 1 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$5.64 (bear) to HK$9.85 (bull), the price of HK$2.65 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 79/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd reported revenue of 902M CNY in FY2025 versus 705M CNY in FY2021, a compound +6.3%/yr. Reported net income was 199M CNY in FY2025, compounding +8.5%/yr from FY2021.

Key figures

Market cap HK$1.5B (≈ $189M) Micro · P/E ratio 6.1 · P/S ratio 1.35 · Dividend yield 9.2% · Net margin 22.1% · Return on equity 12.3% · Return on assets (EBIT) 8.4% (5-year average) · Operating margin 34.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (low confidence).

What moves the price

The share trades about 3% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 200%, 8049 screens cheaper than that median.

Fair Value models

Bear HK$5.64 Fair Value HK$7.94 Bull HK$9.85

Price HK$2.65 · Upside +199.6%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

FCF DCF HK$6.06 HK$8.82 HK$12.53 80

Growth DCF HK$6.04 HK$8.58 HK$11.84 79

Owner Earnings HK$6.43 HK$9.37 HK$13.33 77

All 26 models by family

DCF Models

FCF DCF HK$6.06 HK$8.82 HK$12.53 80

Owner Earnings HK$6.43 HK$9.37 HK$13.33 77

5Y Revenue Exit HK$4.88 HK$7.28 HK$10.32 73

5Y EBITDA Exit HK$5.46 HK$8.39 HK$11.82 75

5Y P/E Exit HK$6.26 HK$9.94 HK$13.87 70

10Y Revenue Exit HK$5.21 HK$7.39 HK$10.31 67

10Y EBITDA Exit HK$5.64 HK$8.08 HK$11.35 68

10Y P/E Exit HK$6.10 HK$9.04 HK$12.77 64

Earnings-Based

Graham-Dodd HK$2.83 HK$10.21 HK$13.76 64

Lynch FV HK$2.41 HK$3.45 HK$4.48 61

PEG = 1.0 HK$2.41 HK$3.45 HK$4.48 57

EPV HK$2.64 HK$2.94 HK$3.18 74

Dividend Discount

Gordon GGM HK$1.82 HK$3.15 HK$4.19 68

DDM Multi-Stage HK$1.82 HK$2.94 HK$3.38 67

Multiples

P/E Multiple HK$6.87 HK$9.16 HK$11.45 63

P/S Multiple HK$4.96 HK$6.61 HK$8.26 58

P/B Multiple HK$11.57 HK$15.42 HK$19.28 55

EV/EBIT HK$6.03 HK$7.94 HK$9.85 66

EV/EBITDA HK$5.64 HK$7.42 HK$9.20 67

EV/Revenue HK$4.27 HK$5.97 HK$7.66 54

Asset-Based

NCAV (Graham) HK$0.3300 HK$0.5000 HK$0.6300 54

Growth DCF

Growth DCF HK$6.04 HK$8.58 HK$11.84 79

Rev-Margin DCF HK$4.88 HK$7.32 HK$10.25 73

Economic Profit

Residual Income HK$3.01 HK$3.34 HK$3.98 76

ROIC Compounder HK$2.64 HK$2.94 HK$3.18 72

Growth Earnings

Growth-Adj P/E HK$4.73 HK$6.76 HK$8.78 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 79/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 52

How much profit the company makes from its sales and capital

Quality Growth 64

Are margins and returns getting better?

Cashflow 93

Do the profits arrive as real cash?

Financial strength 77

Debt, balance sheet and risk of trouble

Investment 91

Does it invest with discipline instead of growing at any price?

Low Volatility 81

How calm the share price moves, does not count

Price momentum 65

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 84

Distance to the 52-week high, does not count

New shares 82

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+2.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+2.3%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.7%

Start year 2020 (pandemic). Over 10 years: +5.3% a year

Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.2%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+16.0%

Earnings growth per share plus dividend.

Earnings per share, growth per year+6.8%

Dividend (yield on the price)9.2%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6.8% vs 4.1%, steady

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 24%

Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

−31.0%

The company could shrink this much every year for the next five years and today's price would still be justified.

What forecasts expect

n/a

No analyst forecast available.

After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −32.2% a year for the price.

Watch 8049, get fair value alerts →

Compare Jilin Province Huinan Changlong Bio-pharmacy Co Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 13/14 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 79 · Top 25%

Fair Value upside +199.6% · Top 25%

Profitability

Return on equity (12 months) 12.3% · Above median

Return on assets 7.5% · Above median

Net margin (12 months) 24.4% · Top 25%

Operating margin (12 months) 34.9% · Top 25%

Growth and dividend

Revenue growth (quarter YoY) −0.9% · Below median

Dividend yield (12 months) 9.2% · Top 25%

Balance sheet

Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 6.1× · Cheapest 25%

P/B 0.75× · Cheapest 25%

P/S (12 months) 1.41× · Cheaper than median

Price / free cash flow (fiscal year) 4.2× · Cheapest 25%

EV/EBITDA 4.2× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 15

FUTURE (revenue growth)0 · sector 25

PAST (return on equity)49 · sector 29

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)100 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Zoetis Inc ZTS	$79.40	$113.53	+43%	vs 8049
Jiangsu Hengrui Pharmaceuticals Co 600276	¥50.43	¥55.21	+9%	vs 8049
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,860	₹1,947	+5%	vs 8049
Haleon plc HLN	$9.14	$8.61	−6%	vs 8049
Merck KGaA MRK	€148.75	€109.18	−27%	vs 8049
Galderma Group GALD	CHF 191.75	CHF 109.86	−43%	vs 8049
Takeda Pharmaceutical Company TAK	$21.02	$11.31	−46%	vs 8049
Teva Pharmaceutical Industries Limited TEVA	$42.61	$20.74	−51%	vs 8049
Sandoz Group SDZ	CHF 83.78	CHF 39.70	−53%	vs 8049
Divi's Laboratories Limited DIVISLAB	₹10,321	₹1,567	−85%	vs 8049

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/8049?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/8049.HK.svg" width="360" height="84" alt="Jilin Province Huinan Changlong Bio-pharmacy Co Ltd: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "Jilin Province Huinan Changlong Bio-pharmacy Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8049

Frequently asked questions

Is Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) overvalued or undervalued?

As of Nov 8, 2026, our model estimates a fair value of HK$7.94 versus a price of HK$2.65, about +200% upside (undervalued).

What is the fair value of 8049?

Our model-based fair value for Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is HK$7.94 (as of Nov 8, 2026), built from audited fundamentals. The current price: HK$2.65.

What is the quality score of 8049?

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd has a Quality Score of 79/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

Our model-based price target is the fair value of HK$7.94 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario HK$5.64, optimistic scenario HK$9.85. It is a calculation from audited fundamentals, not an analyst target.

What is the Jilin Province Huinan Changlong Bio-pharmacy Co Ltd stock forecast for 2026?

Our models put fair value at HK$7.94, about +200% upside versus a price of HK$2.65 (undervalued). Cautious scenario HK$5.64, optimistic scenario HK$9.85. The calculation is refreshed regularly with new filings.

What is the revenue of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd reported trailing-twelve-month revenue of about 898M CNY (latest available figure, as of Nov 8, 2026).

Does Jilin Province Huinan Changlong Bio-pharmacy Co Ltd pay a dividend?

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd currently shows a dividend yield of 9.21% relative to its recent price (as of Nov 8, 2026).

How much is the dividend of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd has a dividend yield of 9.2%.

What growth is priced into Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

For today's price to be fair in a discounted-cash-flow model, Jilin Province Huinan Changlong Bio-pharmacy Co Ltd would have to grow free cash flow by -31.0 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.7 % per year. As of Nov 8, 2026.

What discount rate (WACC) does the fair value of 8049 use?

Our models discount Jilin Province Huinan Changlong Bio-pharmacy Co Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.29, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jilin Province Huinan Changlong Bio-pharmacy Co Ltd that is -31.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.

How much growth has Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) delivered so far?

Over the past 5 years revenue at Jilin Province Huinan Changlong Bio-pharmacy Co Ltd grew +7.7 % a year. The price currently implies free-cash-flow growth of -31.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) growing?

The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (-31.0 % per year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

The free-cash-flow yield on the price is 23.82 %: that much free cash flow Jilin Province Huinan Changlong Bio-pharmacy Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jilin Province Huinan Changlong Bio-pharmacy Co Ltd it is HK$7.94 per share (as of Nov 8, 2026), against a price of HK$2.65. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).

Is Jilin Province Huinan Changlong Bio-pharmacy Co Ltd stock overvalued or undervalued in 2026?

As of Nov 8, 2026, 8049 trades below its calculated fair value: price HK$2.65, fair value HK$7.94, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 8049?

No. The price is what the market pays today (HK$2.65); the fair value is what the company's own numbers justify (HK$7.94). For Jilin Province Huinan Changlong Bio-pharmacy Co Ltd the two are HK$5.29 per share apart. That gap is exactly why we show both numbers side by side.

How much is Jilin Province Huinan Changlong Bio-pharmacy Co Ltd worth?

The market values Jilin Province Huinan Changlong Bio-pharmacy Co Ltd at about HK$1.5B (market capitalisation, as of Nov 8, 2026). Per share that is HK$2.65; our models calculate a fair value of HK$7.94 per share.

What do the bullish and bearish scenarios say about 8049?

Our models span a range for Jilin Province Huinan Changlong Bio-pharmacy Co Ltd: cautious scenario HK$5.64, base HK$7.94, optimistic HK$9.85 per share (as of Nov 8, 2026, price HK$2.65). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 8049?

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd trades at a price-to-earnings ratio of 6.1 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$7.94 is built from several models across several years. Other multiples: P/B 0.8, P/S 1.4, EV/EBITDA 4.2.

How solid is the balance sheet of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

Balance-sheet figures for Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (as of Nov 8, 2026): return on equity 12.3%, debt of 0.00 per unit of equity. They feed the Quality Score of 79/100, which measures business quality independently of the share price.

How far is 8049 from its 52-week high?

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd trades at HK$2.65, about 3% below its 52-week high of HK$2.73 and 49% above the low of HK$1.78 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$7.94 is for.

Which stocks are comparable to Jilin Province Huinan Changlong Bio-pharmacy Co Ltd?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Jilin Province Huinan Changlong Bio-pharmacy Co Ltd stock attractive at the current price?

The data as of Nov 8, 2026: price HK$2.65, calculated fair value HK$7.94 (+200%), Quality Score 79/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 8049 calculated?

We run Jilin Province Huinan Changlong Bio-pharmacy Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$7.94 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.3% above its aggregate fair value. Jilin Province Huinan Changlong Bio-pharmacy Co Ltd currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

The closing price on Nov 6, 2026 was HK$2.65. Our model-based fair value is HK$7.94, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Jilin Province Huinan Changlong Bio-pharmacy Co Ltd right now?

The rarer combination: high quality (79/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (HK$5.64). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Where does the earnings growth of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) come from?

Earnings per share at Jilin Province Huinan Changlong Bio-pharmacy Co Ltd grew +3.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.3 %, EBIT margin −1.0 %, tax rate −0.7 %, residual (interest, one-offs) +0.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd

How large is the market capitalisation of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

The market capitalisation of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is HK$1.5B (≈ $189M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

The price-to-sales ratio of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is 1.35 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the dividend yield of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

The dividend yield of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is 9.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

The net margin of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is 22.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

The return on equity (ROE) of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is 12.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

On an EBIT basis the return on assets of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is 8.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

The operating margin of Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is 34.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

Revenue at Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is growing −0.9% versus a year earlier (3y avg +2.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049)?

Earnings per share at Jilin Province Huinan Changlong Bio-pharmacy Co Ltd are growing +19.3% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) hold?

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd holds more cash than debt, 143M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Jilin Province Huinan Changlong Bio-pharmacy Co Ltd in the live analysis

One click puts Jilin Province Huinan Changlong Bio-pharmacy Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.